中华放射肿瘤学杂志
Friday, Apr. 4, 2025   Home | Journal | Editorial | Instruction | Subscription | Advertisement | Academic | Index-in | Contact Us | Chinese
Chinese Journal of Radiation Oncology  2017, Vol. 26 Issue (1): 35-39    DOI: 10.3760/cma.j.issn.1004-4221.2017.01.007
Thoracic Tumors Current Issue| Next Issue| Archive| Adv Search [an error occurred while processing this directive] | [an error occurred while processing this directive]
The prognostic impacts of IMRT combined with chemotherapy with different platinums and paclitaxel in advanced esophageal carcinoma
Chen Junqiang,Su Tingfeng,Lin Yu,Wang Bingyi,Pan Jianji
Department of Radiotherapy(Su Tingfeng Current Employer:Department of Oncology,Huadu district,Guangzhou City People’s Hospital,510800,Guangzhou 510800,China),Teaching Hospital of Fujian Medical University,Fujian Provincial Cancer Hospital,Fuzhou 350014,China
Download: PDF (979 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      Supporting Info
Abstract  

Objective To analyze the prognosis of advanced esophageal carcinoma treated with paclitaxel and different platinum-based chemotherapy regimens plus intensity-modulated radiotherapy (IMRT), and to explore an optimal chemotherapy regimen. Methods A total of 242 patients with advanced esophageal carcinoma who were admitted to our hospital and treated with paclitaxel and cisplatin (68 patients), nedaplatin (85 patients), lobaplatin (58 patients), or oxaliplatin (31 patients) plus IMRT from 2008 to 2014 were enrolled as subjects. The prognosis of the four groups was analyzed after 2, 3, and ≥4 cycles of chemotherapy. The survival rates were calculated by the Kaplan-Meier method and analyzed by the log-rank test. The Cox model was used for the multivariate prognostic analysis. Results The sample number of 3 years was 168 cases. In all the 242 patients, the medium survival time was 31.1 months and the 3-year overall survival (OS) rate was 47.4%. There was no significant difference in the 3-year OS rate between the cispaltin, nedaplatin, lobaplatin, and oxaliplatin groups (46.2% vs. 56.4% vs. 45.7% vs. 29.0%, P=0.090). The stratified analysis showed that the cisplatin, nedaplatin, and lobaplatin groups had a significantly higher OS rate than the oxaliplatin group (50.1% vs. 29.0%, P=0.021). There was no significant difference in the 3-year OS rate between patients receiving 2, 3, and ≥4 cycles of chemotherapy (40.1% vs. 49.5% vs. 50.8%, P=0.264). The multivariate analysis showed that esophageal tumor volume and the maximal size of metastatic lymph node were independent prognostic factors. Conclusions Combined with IMRT, paclitaxel plus cisplatin, nedaplatin, or lobaplatin-based chemotherapy achieves improved survival rates than paclitaxel plus oxaliplatin-based chemotherapy. Esophageal tumor volume and the maximal size of metastatic lymph node are independent prognostic factors.

Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Chen Junqiang
Su Tingfeng
Lin Yu
Wang Bingyi
Pan Jianji
Key wordsEsophageal neoplasms/chemotherapy      Esophageal neoplasms/intensity-modulated radiotherapy      Prognostic analysis     
Received: 12 May 2016     
Corresponding Authors: Chen Junqiang,Email:junqiangc@163.com   
Cite this article:   
Chen Junqiang,Su Tingfeng,Lin Yu et al. The prognostic impacts of IMRT combined with chemotherapy with different platinums and paclitaxel in advanced esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(1): 35-39.
Chen Junqiang,Su Tingfeng,Lin Yu et al. The prognostic impacts of IMRT combined with chemotherapy with different platinums and paclitaxel in advanced esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(1): 35-39.
URL:  
http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.01.007     OR     http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I1/35
  Copyright © 2010 Editorial By Chinese Journal of Radiation Oncology
Support by Beijing Magtech Co.ltd  support@magtech.com.cn